MX2019004802A - Determinacion de dosis para los agentes inmunoterapeuticos. - Google Patents

Determinacion de dosis para los agentes inmunoterapeuticos.

Info

Publication number
MX2019004802A
MX2019004802A MX2019004802A MX2019004802A MX2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A
Authority
MX
Mexico
Prior art keywords
immunotherapeutic agents
dose determination
administration
variations
immunotherapeutic
Prior art date
Application number
MX2019004802A
Other languages
English (en)
Inventor
Sahin Ugur
Josef Christof Friedrich Strobl Stefan
Peter Rösemann Roman
Jahndel Veronika
Schwarck-Kokarakis Doreen
Hüsemann Yves
Dorer Kathrin
Jabulowsky Robert
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MX2019004802A publication Critical patent/MX2019004802A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/56—IFN-alpha
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con los métodos para determinar las dosis apropiadas para la administración de compuestos inmunoterapéuticos, en los que la efectividad y la toxicidad pueden variar notablemente con la misma dosis entre individuos por las variaciones naturales de los sujetos individuales, así como las variaciones en la reacción del sistema inmune en respuesta a la administración de dichos compuestos inmunoterapéuticos.
MX2019004802A 2016-10-25 2017-10-25 Determinacion de dosis para los agentes inmunoterapeuticos. MX2019004802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/075647 WO2018077385A1 (en) 2016-10-25 2016-10-25 Dose determination for immunotherapeutic agents
PCT/EP2017/077293 WO2018077942A1 (en) 2016-10-25 2017-10-25 Dose determination for immunotherapeutic agents

Publications (1)

Publication Number Publication Date
MX2019004802A true MX2019004802A (es) 2020-02-05

Family

ID=57288372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004802A MX2019004802A (es) 2016-10-25 2017-10-25 Determinacion de dosis para los agentes inmunoterapeuticos.

Country Status (10)

Country Link
US (1) US20200191798A1 (es)
EP (1) EP3532844A1 (es)
JP (2) JP7203721B2 (es)
KR (3) KR20230035691A (es)
CN (1) CN109891238A (es)
AU (1) AU2017350137B2 (es)
BR (1) BR112019007132A8 (es)
CA (1) CA3040203A1 (es)
MX (1) MX2019004802A (es)
WO (2) WO2018077385A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110305841B (zh) * 2019-07-12 2020-08-25 赛德特生物科技开发有限公司 可以清除体内隐性感染的免疫细胞及其制备方法与应用
CA3223943A1 (en) 2021-07-29 2023-02-02 Ugur Sahin Compositions and methods for treatment of melanoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US7465446B2 (en) * 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US9463226B2 (en) * 2006-03-28 2016-10-11 Peter Hersey Method for treating stage IV melanoma
ES2872377T3 (es) 2008-05-26 2021-11-02 Univ Zuerich Nanopartículas de protamina/ARN para inmunoestimulación
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
ES2735438T3 (es) * 2009-12-23 2019-12-18 Cellestis Ltd Un ensayo para medir la capacidad de respuesta inmune mediada por células
JP5975983B2 (ja) * 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ， インコーポレイテッド 固形腫瘍を処置するための方法
WO2012073257A2 (en) * 2010-11-30 2012-06-07 Bharat Biotech International Limited Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
US9345755B2 (en) * 2012-02-20 2016-05-24 University Of Virginia Patent Foundation Composition and methods for treating melanoma
WO2014039983A1 (en) * 2012-09-07 2014-03-13 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
CA2890911A1 (en) * 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN103417956A (zh) * 2013-07-23 2013-12-04 尹先哲 Cik细胞与中等剂量白介素-2回输联合序贯化疗治晚期非小细胞肺癌的应用
CN104800243B (zh) * 2014-01-28 2021-04-30 中国人民解放军军事医学科学院基础医学研究所 一种重组间充质干细胞在制备免疫抑制剂中的应用
WO2016155809A1 (en) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
JP2019537712A (ja) 2019-12-26
RU2019115822A3 (es) 2020-12-30
RU2019115822A (ru) 2020-11-27
BR112019007132A8 (pt) 2022-08-16
KR20240007297A (ko) 2024-01-16
CA3040203A1 (en) 2018-05-03
BR112019007132A2 (pt) 2019-07-02
CN109891238A (zh) 2019-06-14
US20200191798A1 (en) 2020-06-18
AU2017350137A1 (en) 2019-04-11
AU2017350137B2 (en) 2024-04-18
KR20230035691A (ko) 2023-03-14
WO2018077942A1 (en) 2018-05-03
WO2018077385A1 (en) 2018-05-03
EP3532844A1 (en) 2019-09-04
JP2023015152A (ja) 2023-01-31
KR20190073376A (ko) 2019-06-26
JP7203721B2 (ja) 2023-01-13

Similar Documents

Publication Publication Date Title
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MY191581A (en) Anti-pd-1 antibodies
MY187540A (en) Compounds active towards bromodomains
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
TN2015000402A1 (fr) Methods for treating crohn's disease using an anti-il23 antibody
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
EA201892327A1 (ru) Ингаляционные и назальные бензодиазепины
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2019004802A (es) Determinacion de dosis para los agentes inmunoterapeuticos.
MX2018004308A (es) Peptido derivado de foxm1 y vacuna que lo incluye.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2019014291A (es) Metodo de tratamiento.
NZ721832A (en) Solid forms of tenofovir
PH12017501979A1 (en) Pharmaceutical compound
MX2018004802A (es) Nuevo adyuvante y composición de vacuna que contiene el mismo.
TN2018000091A1 (en) Oxa-diazaspiro compounds having activity against pain
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
RU2014138694A (ru) Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей
JOP20200126A1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.